OptiBiotix, a developer of human microbiome modulators, has signed a manufacturing and supply agreement with SACCO to market its cholesterol-reducing probiotic strain LP LDL to the more than 2,500 food, beverage, consumer healthcare, and pharmaceutical companies it serves across Europe.
IFT Daily News
Leave a Comment